About: Purine based inhibitors of cyclin-dependent kinases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Purine based inhibitors of cyclin-dependent kinases Goto Sponge Distinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Inhibition of cyclin-dependent kinases (CDK's), the most promising drug target of the new era, became one of the most suitable methods for stopping the division of cancer cells. Several families of low molecular weight compounds were identified as specific CDK inhibitors, sharing a common ATP competing mechanism [1-2]. Some of them have already undergone in vivo efficacy studies, preclinical and clinical evaluation, and thus confirmed the selected CDK's as a proper target for development of new anticancer drugs. Up to now the advancement of purine CDK inhibitors has been based mainly on modifications of substituents at positions 2, 6 and 9, respectively [1-3]. To extend the inhibitor-CDK mutual interactions in a different manner, we introduced anotherside chain at C-8 of purine and rearranged the purine heteroatoms, respectively. Inhibition of cyclin-dependent kinases (CDK's), the most promising drug target of the new era, became one of the most suitable methods for stopping the division of cancer cells. Several families of low molecular weight compounds were identified as specific CDK inhibitors, sharing a common ATP competing mechanism [1-2]. Some of them have already undergone in vivo efficacy studies, preclinical and clinical evaluation, and thus confirmed the selected CDK's as a proper target for development of new anticancer drugs. Up to now the advancement of purine CDK inhibitors has been based mainly on modifications of substituents at positions 2, 6 and 9, respectively [1-3]. To extend the inhibitor-CDK mutual interactions in a different manner, we introduced anotherside chain at C-8 of purine and rearranged the purine heteroatoms, respectively. (en)
Title	Purine based inhibitors of cyclin-dependent kinases Purine based inhibitors of cyclin-dependent kinases (en)
skos:prefLabel	Purine based inhibitors of cyclin-dependent kinases Purine based inhibitors of cyclin-dependent kinases (en)
skos:notation	RIV/61989592:15310/03:00001572!RIV/2004/GA0/153104/N
http://linked.open.../vavai/riv/strany	11
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(GA301/02/0475), P(GA303/02/0875)
http://linked.open...vai/riv/dodaniDat	2004
http://linked.open...aciTvurceVysledku	Kryštof, Vladimír Hanuš, Jan Strnad, Miroslav Otyepka, Michal Lenobel, René
http://linked.open.../riv/druhVysledku	D - Článek ve sborníku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Přírodovědecká fakulta
http://linked.open...dnocenehoVysledku	624286
http://linked.open...ai/riv/idVysledku	RIV/61989592:15310/03:00001572
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Purine, inhibitors, CDK (en)
http://linked.open.../riv/klicoveSlovo	inhibitors Purine CDK
http://linked.open...ontrolniKodProRIV	[33962E260322]
http://linked.open...v/mistoKonaniAkce	Madrid
http://linked.open...i/riv/mistoVydani	Madrid
http://linked.open...i/riv/nazevZdroje	TARGETED SEARCH FOR ANTICANCER DRUGS
http://linked.open...in/vavai/riv/obor	ED
http://linked.open...ichTvurcuVysledku	5 (xsd:int)
http://linked.open...cetTvurcuVysledku	11 (xsd:int)
http://linked.open...ocetUcastnikuAkce	0 (xsd:int)
http://linked.open...nichUcastnikuAkce	0 (xsd:int)
http://linked.open...vavai/riv/projekt	Development of new generation of cyclin-dependent kinase inhibitors: structure-activity relationships, molecular and in vitro mechanisms of action Purine inhibitors of cyclin-dependent kinases as anticancer and antimitotic compounds
http://linked.open...UplatneniVysledku	2003
http://linked.open...iv/tvurceVysledku	Hanuš, Jan Kryštof, Vladimír Otyepka, Michal Strnad, Miroslav Lenobel, René Moravec, J. Fuksová, K. Havlíček, L. Vermeulen, K. Berneman, Z. Moravcová, D.
http://linked.open...vavai/riv/typAkce	WRD - Světová
number of pages	91 (xsd:int)
http://purl.org/ne...btex#hasPublisher	Centro Nacional de Investigaciones Oncológicas Carlos III.
http://localhost/t...ganizacniJednotka	15310

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 85 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software